Sudeep Pharma Share Debuts At Rs 730 On NSE With 23% Premium, Should You Buy, Hold Or Sell?

Sudeep Pharma Share Price: Shares of Sudeep Pharma made a strong debut on Friday, November 28, to list at 23 per cent premium. On NSE, shares are listed at Rs 730, with a premium of 23.10 per cent.

On the other hand, shares opened at Rs 733.95 per piece on BSE, reflecting a premium of 23.76 per cent.

Following the listing, shares moved north to climb to Rs 738 per share intraday.

The Sudeep Pharma IPO, which closed on Tuesday, received 93.71x subscription, garnering bids for 99,00,86,575 shares as against the 1,05,64,927 shares on offer. Its retail category got a 15.65x subscription, while its non-institutional investor (NII) quota got a 116.72x subscription. The QIB category received a 213.08x subscription.

Sudeep Pharma Shares: Should You Buy, Hold Or Sell?

Sudeep Pharma IPO: More Details

Shivani Nyati, Head of Wealth at Swastika Investmart in post listing IPO noted said, Sudeep Pharma delivered an impressive listing on the stock exchanges, opening at Rs 733.95 on the BSE and Rs 730 on the NSE, marking a 24% premium over its IPO price of Rs 593 per share. The strong debut reflects robust investor confidence in the company’s position as a leading player in specialty pharma ingredients and excipients.

Before the issue opened, the company raised Rs 268.5 crore from anchor investors, further reinforcing investor confidence.

Sudeep Pharma’s listing strength is backed by its established presence in pharma and nutraceutical input materials, diversified product portfolio, long-term relationships with leading global pharma companies, and strong export potential. However, in the near term, investors may remain watchful of margin sustainability, raw material price swings, and competitive intensity in specialty chemicals and pharma ingredients.

Given the strong listing pop, investors allocated shares may consider booking partial gains, while aggressive long-term investors bullish on the specialty pharma ingredient space may hold the remaining portion — with a disciplined stop-loss at Rs 690.

Sudeep Pharma IPO Details

The three-day initial public offering (IPO) concluded on November 25.

The IPO is a mix of a fresh issue of equity shares worth Rs 95 crore and an offer for sale of nearly 1.35 crore equity shares aggregating worth Rs 800 crore by promoters, Sujit Jaysukh Bhayani, Sujeet Jaysukh Bhayani HUF, Shanil Sujit Bhayani and Avani Sujit Bhayani.

The net proceeds from the fresh issue to the tune of Rs 75.81 crore will be for capital expenditure towards procurement of machinery for its production line located at Nandesari Facility 1, Gujarat and general corporate

purposes.

Sudeep Pharma is a technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing to the global healthcare ecosystem.

The company is one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors, in terms of production capacity with a combined annual available manufacturing capacity of 72,246 metric tons, as of June 30, 2025, as per F&S report.

It has served over 1,100 customers, and has built longstanding relationships with marquee customers including Pfizer Inc, Mankind Pharma, Merck Group, Aurobindo Pharma, Cadila Pharmaceutical, IMCD Asia Pte Ltd, and Danone SA.

ICICI Securities Ltd and IIFL Capital Services are the book-running lead managers, and MUFG Intime India Pvt Ltd is the registrar of the IPO.

Disclaimer: The views and investment tips by experts in this News18.com report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions.